Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H36N6O6 |
Molecular Weight | 528.6006 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(CC)CNC(=O)CN1C=CC=C(NC(=O)[C@H](CC\C=C\C(=O)OC)NC(=O)C2=CN=CN2C)C1=O
InChI
InChIKey=VHGWUSABWIEXKQ-BEBFYNPSSA-N
InChI=1S/C26H36N6O6/c1-5-18(6-2)14-28-22(33)16-32-13-9-11-20(26(32)37)30-24(35)19(10-7-8-12-23(34)38-4)29-25(36)21-15-27-17-31(21)3/h8-9,11-13,15,17-19H,5-7,10,14,16H2,1-4H3,(H,28,33)(H,29,36)(H,30,35)/b12-8+/t19-/m0/s1
Molecular Formula | C26H36N6O6 |
Molecular Weight | 528.6006 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:55:07 GMT 2023
by
admin
on
Sat Dec 16 11:55:07 GMT 2023
|
Record UNII |
T4SR539YKF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
T4SR539YKF
Created by
admin on Sat Dec 16 11:55:07 GMT 2023 , Edited by admin on Sat Dec 16 11:55:07 GMT 2023
|
PRIMARY | |||
|
300000042592
Created by
admin on Sat Dec 16 11:55:07 GMT 2023 , Edited by admin on Sat Dec 16 11:55:07 GMT 2023
|
PRIMARY | |||
|
ZED-1227
Created by
admin on Sat Dec 16 11:55:07 GMT 2023 , Edited by admin on Sat Dec 16 11:55:07 GMT 2023
|
PRIMARY | |||
|
72950407
Created by
admin on Sat Dec 16 11:55:07 GMT 2023 , Edited by admin on Sat Dec 16 11:55:07 GMT 2023
|
PRIMARY | |||
|
1542132-88-6
Created by
admin on Sat Dec 16 11:55:07 GMT 2023 , Edited by admin on Sat Dec 16 11:55:07 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Zedira GmbH; Developer: Dr Falk Pharma, University Medical Center of the Johannes Gutenberg University Mainz, Zedira GmbH; Class: Small molecule; Mechanism of Action: Trans-glutaminase 2 inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Coeliac disease; Most Recent Event: No Data Available
|
||
|
ACTIVE MOIETY |
Zedira, Dr. Falk Pharma and the University of Mainz Hospital, which together comprise a flagship project of the Ci3 leading-edge cluster, are to receive additional subsidy funding for clinical development of a celiac disease drug.
|